Royalty Pharma plc (RPRX)
NASDAQ: RPRX · IEX Real-Time Price · USD
27.82
0.00 (0.00%)
At close: Apr 23, 2024, 4:00 PM
28.20
+0.38 (1.37%)
After-hours: Apr 23, 2024, 6:37 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 46.75, with a low estimate of 38 and a high estimate of 57. The average target predicts an increase of 68.04% from the current stock price of 27.82.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +36.59% | Apr 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $45 → $42 | Buy | Maintains | $45 → $42 | +50.97% | Feb 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $56 → $50 | Strong Buy | Maintains | $56 → $50 | +79.73% | Feb 20, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $54 → $57 | Buy | Maintains | $54 → $57 | +104.89% | Nov 9, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $53 → $54 | Buy | Maintains | $53 → $54 | +94.10% | Oct 11, 2023 |
Financial Forecast
Revenue This Year
2.68B
from 2.35B
Increased by 13.74%
Revenue Next Year
2.93B
from 2.68B
Increased by 9.41%
EPS This Year
3.85
from 2.53
Increased by 52.11%
EPS Next Year
4.20
from 3.85
Increased by 9.24%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.9B | 3.4B | 3.8B |
| Avg | 2.7B | 2.9B | 3.2B |
| Low | 2.3B | 2.5B | 2.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 24.5% | 26.5% | 29.4% |
| Avg | 13.7% | 9.4% | 10.7% |
| Low | -0.4% | -6.0% | -4.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.40 | 4.98 | 5.59 | 4.88 | 5.03 |
| Avg | 3.85 | 4.20 | 4.60 | 4.74 | 4.89 |
| Low | 2.91 | 2.74 | 2.91 | 4.56 | 4.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.9% | 29.3% | 32.9% | 6.2% | 6.0% |
| Avg | 52.1% | 9.2% | 9.3% | 3.2% | 3.0% |
| Low | 15.0% | -28.7% | -30.8% | -0.9% | -1.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.